CM
RLMD icon

Caption Management’s Relmada Therapeutics RLMD Stock Holding History

Caption Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,600
Closed -$355K – 1989
2025
Q4 		$355K Buy
+73,600
New +$247K ﹤0.01% 1299
2023
Q1 		– Sell
-888,800
Closed -$3.1M – 1480
2022
Q4 		$3.1M Buy
888,800
+663,400
+294% +$5.83M 0.05% 440
2022
Q3 		$8.35M Sell
225,400
-325,500
-59% -$9.02M 0.12% 210
2022
Q2 		$10.5M Buy
550,900
+290,700
+112% +$6.34M 0.14% 180
2022
Q1 		$7.02M Buy
+260,200
New +$5.38M 0.08% 320
2021
Q3 		– Sell
-58,500
Closed -$1.87M – 1757
2021
Q2 		$1.87M Buy
58,500
+47,900
+452% +$1.66M 0.02% 696
2021
Q1 		$373K Buy
+10,600
New +$371K 0.01% 859
2020
Q1 		– Sell
-25,000
Closed -$975K – 1043
2019
Q4 		$975K Buy
+25,000
New +$760K 0.03% 507

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Caption Management's RLMD Position: Q3 2021 in Review

Caption Management sold out of Relmada Therapeutics (RLMD) in Q3 2021, closing a stake of 5,889 shares — an estimated $189K sold.

Caption Management first reported a position in RLMD in Q1 2021 and held it in 2 quarters. The position peaked at $208K in Q1 2021. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2021.

  • Caption Management reported no remaining Relmada Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Caption Management sold 5,889 Relmada Therapeutics shares in Q3 2021, an estimated $189K.
  • Caption Management first reported a position in Relmada Therapeutics in Q1 2021 and held it in 2 quarters.
  • Caption Management's Relmada Therapeutics position peaked at $208K in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2021.

Based on Caption Management's 13F filing for Q3 2021, filed 12 Nov 2021.